N@N

Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care Conference

^{Published on 2013-02-27 13:16:34 - Market Wire}
 

Sangamo BioSciences Announces Presentation At 33rd Annual Cowen And Company Health Care... -- RICHMOND, Calif., Feb. 27, 2013 /PRNewswire/ --

[ ]

[ Download image ]

RICHMOND, Calif., Feb. 27, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: [ SGMO ]) announced today that Geoff Nichol , M.B., Ch.B., Sangamo's executive vice president, research and development, will provide an update on the progress of Sangamo's ZFP Therapeutic^® development programs and an overview of the company's business strategy at 10:40 am ET on Wednesday, March 6, 2013, at the 33^rd Annual Cowen and Company Health Care Conference which will be held in Boston.

(Logo: [ http://photos.prnewswire.com/prnh/20130102/SF35903LOGO ])

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under [ Events and Presentations ]. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic^® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at [ www.sangamo.com ].

ZFP Therapeutic^® is a registered trademark of Sangamo BioSciences, Inc.

SOURCE Sangamo BioSciences, Inc.